Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Martino M., Lanza F., DEMİRER T., Moscato T., Secondino S., Pedrazzoli P.

EXPERT OPINION ON BIOLOGICAL THERAPY, vol.15, no.2, pp.195-211, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 15 Issue: 2
  • Publication Date: 2015
  • Doi Number: 10.1517/14712598.2015.971749
  • Journal Name: EXPERT OPINION ON BIOLOGICAL THERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.195-211
  • Keywords: allogeneic hematopoietic stem cell transplant, autologous hematopoietic stem cell transplant, erythropoiesis-stimulating agents, erythropoietin, RECOMBINANT-HUMAN-ERYTHROPOIETIN, BONE-MARROW-TRANSPLANTATION, QUALITY-OF-LIFE, CLINICAL-PRACTICE GUIDELINE, CHEMOTHERAPY-INDUCED ANEMIA, EPOETIN-ALPHA, CANCER-PATIENTS, PERIPHERAL-BLOOD, DARBEPOETIN-ALPHA, INTRAVENOUS IRON
  • Ankara University Affiliated: Yes

Abstract

Introduction: Erythropoiesis-stimulating agents (ESAs) are used in treating cancer- and chemotherapy-induced anemia with the aim of accelerating the recovery of red blood cells (RBCs), reduce the risks associated with RBC transfusions and improve quality of life.